- Home
- PHAR vs EYPT Comparison
PHAR vs EYPT Comparison
Compare PHAR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | EYPT |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PHAR | EYPT |
|---|---|---|
| Price | $17.06 | $14.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $39.00 | $31.80 |
| AVG Volume (30 Days) | 18.0K | ★ 921.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | $1,031.72 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.79 | $4.16 |
| 52 Week High | $21.34 | $19.11 |
Technical Indicators
Market Signals| Indicator | PHAR | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 51.36 |
| Support Level | $16.55 | $13.61 |
| Resistance Level | $17.60 | $14.54 |
| Average True Range (ATR) | 0.64 | 0.74 |
| MACD | 0.13 | 0.15 |
| Stochastic Oscillator | 76.15 | 84.88 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.